Rennova Health, Inc. · OTC:RNVA
Rennova Health — Investor Presentation (September 2016)
24 slides from Rennova Health's investor presentation, Sep 27, 2016
Slide 1: Diagnostics and Supportive Software Solutions to Healthcare Providers
Nasdaq: RNVA Diagnostics and Supportive Software Solutions to Healthcare Providers Sept 2016
Slide 2: Forward-Looking Statements and Non-GAAP Information
This presentation includes forward - looking statements about Rennova Health’s anticipated results that involve risks and uncertainties . Some of the information contained in this presentation, including statements as to industry trends and plans, objectives, expectations and strategy for the combin
Slide 3: Who We Are
Headquartered in West Palm Beach, Florida Rennova Health (Nasdaq RNVA, RNVAZ) is a healthcare service provider offering a suite of integrated services including but not limited to, Diagnostics, EHR, Laboratory Information Systems software, cancer diagnostics interpretation and medical billing servic
Slide 4: Investment highlights
• Approximately $ 8 M invested in our Laboratories in 2014 and 2015 , with no further significant investment required to enable substantial increases in diagnostics testing . • Approximately $ 5 M invested in our software products in 2014 and 2015 . Investment is ongoing but products are complete an
Slide 5: Single Source Solution for Medical Providers
• The diagnostics sector has changed dramatically in the last few years • Paper records and faxes meant different vendors to a medical provider could function side by side without communication • Electronic platforms and integration have created a need for providers of solutions to communicate effic
Slide 6: Single Source Solution for Medical Providers
Clinical Lab S ervices Revenue Cycle Management Software S olutions Single Source Solution 5 Clinical Laboratories Integrated Medical Billing Company Proprietary Lab ordering and reporting Laboratory Information System (LIS) EHR / Practice Management Solution Interpretation and Decision Support Our
Slide 7: Corporate highlights
Corporate • Received net proceeds of approximately $7.3M in July from a public offering of common shares and warrants • Exchanged all Series C Convertible Preferred Stock and 6,451,611 RNVAW warrants with certain downside protection to Series G Convertible Preferred Stock and new warrants that do no
Slide 8: Clinical Laboratory and Software Segments
Clinical Laboratory Operations Segment • Reported increased revenue in the 2 nd quarter of 2016 compared to the 1 st quarter • Continue to experience the benefits of our stance on compliance in light of the current disruption in the toxicology sector – a major focus of our Clinical Laboratory Operat
Slide 9: 2015 Accomplishments
Nasdaq listing Supportive Software Development Completed Lab Development 9 2015 Accomplishments
Slide 10: Drug and Alcohol Rehabilitation Market
Drug and Alcohol Rehabilitation • Large and growing number of facilities in a fragmented market • Total market size estimated at $35 Billion* • Large and growing number of facilities in a fragmented market • Between 14,500 to 16,700 outpatient clinics* • Market growth from high demand: • Over 23 mil
Slide 11: Pain Management Sector
Pain Management Sector • Large and growing number of clinics in a fragmented market • Total Market Size – estimated at $2 - $4 Billion***** • Private clinics in the U.S. estimated between 1,500 and 2,500******** • More than 6,800 doctors specialize in pain management and more than 600,000 doctors ar
Slide 12: Rennova Health Licensing Map
12 Rennova Health Licensing Map
Slide 13: Our Payers
• Initiated Medicaid Licensing & Third Party Payer Initiative in December 2015 • Applied for Medicaid Licenses in 34 States • As of September 21, 2016, we possess Medicaid Licenses in 23 States • Current Third Party Insurance Payer Contracts • Blue Shield of California • Coventry (National Contract)
Slide 14: Strategy
Strategy 14
Slide 15: Long Term Strategy
Create a sustainable relationship with our customers to grow recurring revenue and provide value to our shareholders How? Build from a toxicology - focused company to: 1. A significant and diverse diagnostics business 2. Offering supportive software solutions that add value by generating sustainable
Slide 16: 2016 Goals
• Strengthen Core Diagnostic Business • Capitalize on recent disruption in toxicology sector • Increase Clinical testing • Grow Pharmacogenomics testing with Genomas • Launch DTC (direct to consumer) testing • Accelerate Growth and/or Launch: • Supportive software product sales (EHR in Rehab sector)
Slide 17: Online Training Program Launch to Deliver Increased Sales
Program Objectives: • Ensure consistency in messaging and information • Provide effective and easy to use platform • Make information accessible anytime and from anywhere • Enable opportunity for monitoring and assessment Initially for sales reps, but to be expanded over time for all employees. Goal
Slide 18: Business Development Opportunities
Epinex Diagnostics, Inc. Genomas Genomics based diagnostics - drug management solution Diabetes and rapid diagnostic tests for providers & consumers 18 Business Development Opportunities
Slide 19: History in Numbers
19 History in Numbers 41,889 59,429 37,877 23,030 4,933 14,775 19,749 1,386 2,217 (9,980) (20,000) (10,000) 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 2013 2014 2015 1st half 2015 1st half 2016 Adjusted Revenues Adjusted EBITDA ($000’s)
Slide 20: Select Income Statement Items
20 Select Income Statement Items (in thousands) 2013 2014 2015 6 Months 2015 6 Months 2016 GAAP Net Revenue 41,889$ 57,928$ 18,393$ 23,030$ 4,933$ Reserve for Aged Accounts Receivable - 1,501 19,494 - - Adjusted Revenues 41,889$ 59,429$ 37,887$ 23,030$ 4,933$ GAAP Pretax Income (Loss) 13,829$ 15,382
Slide 21: Capitalization at September 22, 2016
21 Capitalization at September 22, 2016 As of September 22, 2016 Common Shares Outstanding 53,670,931 Common shares underlying Series G Preferred Stock 21,758,222 Dilutive Potential Shares: Stock Options @ WAVG ex. $4.19 22,599,174 Convertible Debt 1,760,000 Warrants @ WAVG ex. $0.44 35,146,062 Tota
Slide 22: Management team
Seamus Lagan CEO • 20 years experience in the restructuring, development and management of startup and small companies Jason Adams CFO • CFO in behavorial health sector and Senior Financial Management of public companies Victoria Nemerson, Esq. Corporate Counsel • 25 years experience as a trial and
Slide 23: Board of Directors
Thomas Mika Chairman of Rennova, CEO of CollabRx (subsidiary) • 10 years as Chairman and CEO of a Nasdaq listed Company • Oversaw a number of public offerings • Bachelor of Science degree in Microbiology, MBA Harvard Seamus Lagan CEO • 20 years experience in the restructuring, development and manage
Slide 24: Investment highlights
• Approximately $ 8 M invested in our Laboratories in 2014 and 2015 , with no further significant investment required to enable substantial increases in diagnostics testing . • Approximately $ 5 M invested in our software products in 2014 and 2015 . Investment is ongoing but products are complete an
Rennova Health — Investor Presentation (September 2016) on 6ix